Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of HyQvia in PID
NCT01175213Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2010
- Primary completion
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Human normal immunoglobulin G in primary immunodeficiency disease (PID) (3 arms), sponsored by Takeda. Primary endpoints: Annual Rate of Serious Bacterial Infections, Annual Rate of All Infections and 1 more. Started Jul 2010; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT01175213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01175213.